Abstract
Immunotherapy, targeting programmed death ligand-1 (PD-L1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), have shown promising antitumor effects and safety in patients with advanced non-small cell lung cancer (NSCLC), while predictive biomarkers remain largely unknown. Here, we investigated the predictive effect of spatial protein expression signature for KN046, a bispecific antibody (bsAb), as second or above line treatment in advanced NSCLC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
